Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Express Scripts
Johnson and Johnson
Baxter
Mallinckrodt

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

HEPARIN SODIUM Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Heparin Sodium patents expire, and when can generic versions of Heparin Sodium launch?

Heparin Sodium is a drug marketed by Abraxis Pharm, Akorn, B Braun Medical Inc, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Hospira Inc, Lilly, Luitpold, Mylan Labs Ltd, Nanjing King-friend, Organon Usa Inc, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny. and is included in sixty-three NDAs.

The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Heparin Sodium

A generic version of HEPARIN SODIUM was launched as heparin sodium by HOSPIRA on December 15th, 2019.

Drug patent expirations by year for HEPARIN SODIUM
Drug Prices for HEPARIN SODIUM

See drug prices for HEPARIN SODIUM

Recent Clinical Trials for HEPARIN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital General “Dr. Miguel Silva” de MoreliaPhase 4
NAUSLIFE HEMODIALYSIS CLINICSPhase 4
Universidad Nacional Autonoma de MexicoPhase 4

See all HEPARIN SODIUM clinical trials

Pharmacology for HEPARIN SODIUM

US Patents and Regulatory Information for HEPARIN SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017346-005 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Solopak HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 087363-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017651-008 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017029-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira HEPARIN SODIUM PRESERVATIVE FREE heparin sodium INJECTABLE;INJECTION 005264-014 Apr 7, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% heparin sodium INJECTABLE;INJECTION 018916-001 Jan 31, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Sagent Pharms HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 090808-003 Jun 30, 2010 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Boehringer Ingelheim
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.